Hai Yan

List of Publications by Year
in descending order

47 papers	18,243 citations	172457 29 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	21982 citing authors

#	Article	IF	Citations
1	IDH1andIDH2Mutations in Gliomas. New England Journal of Medicine, 2009, 360, 765-773.	27.0	5,285
2	An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science, 2008, 321, 1807-1812.	12.6	5,230
3	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	7.1	1,202
4	Altered Telomeres in Tumors with ATRX and DAXX Mutations. Science, 2011, 333, 425-425.	12.6	891
5	Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8817-8822.	7.1	744
6	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 2012, 483, 484-488.	27.8	630
7	Allelic Variation in Human Gene Expression. Science, 2002, 297, 1143-1143.	12.6	618
8	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget, 2012, 3, 709-722.	1.8	532
9	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3270-3275.	7.1	390
10	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget, 2014, 5, 1515-1525.	1.8	237
11	Small changes in expression affect predisposition to tumorigenesis. Nature Genetics, 2002, 30, 25-26.	21.4	234
12	Biological Role and Therapeutic Potential of IDH Mutations in Cancer. Cancer Cell, 2018, 34, 186-195.	16.8	234
13	Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology, 2016, 18, 16-26.	1.2	221
14	A heterozygous IDH1^{R132H/WT} mutation induces genome-wide alterations in DNA methylation. Genome Research, 2012, 22, 2339-2355.	5.5	157
15	The implications of IDH mutations for cancer development and therapy. Nature Reviews Clinical Oncology, 2021, 18, 645-661.	27.6	155
16	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics, 2014, 46, 726-730.	21.4	148
17	Mutant Metabolic Enzymes Are at the Origin of Gliomas. Cancer Research, 2009, 69, 9157-9159.	0.9	132
18	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications, 2018, 9, 2087.	12.8	124

#	Article	IF	Citations
19	Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. Acta Neuropathologica, 2019, 137, 297-306.	7.7	109
20	Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas. Cancer Research, 2013, 73, 496-501.	0.9	108
21	2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations. PLoS ONE, 2011, 6, e16812.	2.5	100
22	Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget, 2010, 1, 265-277.	1.8	96
23	The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Human Pathology, 2015, 46, 1626-1632.	2.0	88
24	Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. Journal of Biological Chemistry, 2014, 289, 23318-23328.	3.4	81
25	The genetic landscape of anaplastic astrocytoma. Oncotarget, 2014, 5, 1452-1457.	1.8	69
26	Allelic variations in gene expression. Current Opinion in Oncology, 2004, 16, 39-43.	2.4	50
27	The integrated genomic and epigenomic landscape of brainstem glioma. Nature Communications, 2020, 11, 3077.	12.8	50
28	The potential of cerebrospinal fluidâ€“based liquid biopsy approaches in CNS tumors. Neuro-Oncology, 2019, 21, 1509-1518.	1.2	46
29	Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research, 2017, 15, 507-520.	3.4	41
30	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. Cancer Research, 2018, 78, 36-50.	0.9	35
31	Sensitive and rapid detection ofTERTpromoter andIDHmutations in diffuse gliomas. Neuro-Oncology, 2019, 21, 440-450.	1.2	27
32	Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. Oncotarget, 2017, 8, 76644-76655.	1.8	27
33	Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe. Nanotechnology, 2019, 30, 275101.	2.6	21
34	Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 694-699.	2.2	18
35	Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. Molecular Cancer Research, 2020, 18, 968-980.	3.4	18
36	Synthesis and Evaluation of a ¹⁸F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET. ACS Medicinal Chemistry Letters, 2018, 9, 606-611.	2.8	17

#	Article	IF	Citations
37	CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. Molecular Cancer Research, 2019, 17, 2042-2050.	3.4	15
38	Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. European Journal of Medicinal Chemistry, 2016, 119, 218-230.	5.5	13
39	Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies. Clinical Cancer Research, 2021, 27, 383-388.	7.0	12
40	HDMX regulates p53 activity and confers chemoresistance to 3-Bis(2-chloroethyl)-1-nitrosourea. Neuro-Oncology, 2010, 12, 956-966.	1.2	11
41	Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis. Acta Neuropathologica, 2018, 135, 285-298.	7.7	10
42	TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. Acta Neuropathologica Communications, 2021, 9, 178.	5.2	8
43	Genomic alterations and the pathogenesis of glioblastoma. Cell Cycle, 2011, 10, 1174-1175.	2.6	4
44	Improved grading of IDH-mutated astrocytic gliomas. Nature Reviews Neurology, 2018, 14, 383-384.	10.1	2
45	Snapshot of the Allele-Specific Variation in Human Gene Expression. , 2005, 311, 031-038.		1
46	Genetics of glioma. , 0, , 1-23.		1
47	Abstract 2103: Distinct methylation patterns correlate with unique clinical and genomic profiles of brainstem gliomas. , 2021, , .		1